Comparative Pharmacology
Head-to-head clinical analysis: NEPHRAMINE 5 4 versus TRAVASOL 8 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHRAMINE 5 4 versus TRAVASOL 8 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
NEPHRAMINE 5.4% vs TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER is a parenteral nutrition solution that provides a source of amino acids, electrolytes, and calories. The amino acids serve as substrates for protein synthesis and energy metabolism, replenishing nitrogen balance and supporting tissue repair and growth.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
Intravenous infusion. Individualized based on protein and electrolyte requirements. Typical adult dose: 500-2000 mL/day of 8.5% amino acid solution, infused at 60-125 mL/hour.
None Documented
None Documented
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Amino acids have short half-lives (minutes to hours) due to rapid metabolism; no single terminal half-life for mixture. Electrolytes have distribution half-lives of minutes.
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Renal: Amino acids are extensively reabsorbed; excess nitrogen is excreted as urea (renal, majority). Electrolytes are excreted renally with reabsorption regulation. Biliary/fecal: Negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution